Lyell Immunopharma to Present at H.C. Wainwright Cell Therapy Conference — Lyell Immunopharma, Inc.

Event summary

Lyell Immunopharma will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026.
The event is scheduled for 1:30 pm Eastern Time and will be webcast live via Lyell’s investor relations page.
Lyell focuses on next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.
LyFE manufacturing facility has capacity to produce over 1,200 CAR T-cell doses annually.

The big picture

Lyell’s participation in the H.C. Wainwright conference underscores its push to position itself as a leader in advanced CAR T-cell therapies. The biotech sector is increasingly focused on overcoming challenges like tumor microenvironment resistance and cell exhaustion, areas where Lyell claims technological advantages. With a late-stage pipeline and significant manufacturing capacity, Lyell aims to capitalize on the growing demand for more effective cancer treatments.

What we're watching

Clinical Progress: How Lyell’s next-generation CAR T-cell therapies perform in late-stage trials will determine their market potential.
Manufacturing Scale: Whether Lyell can sustain its manufacturing capacity to meet commercial demand post-launch.
Industry Trends: The pace at which cell therapy innovations are adopted in treating solid tumors and hematologic malignancies.